Here's why the Imugene (ASX:IMU) share price is up 6% so far this week

Imugene shares are continuing their impressive run…

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Limited (ASX: IMU) share price has jumped out of the starting blocks from the opening of trade this week.

Whereas the S&P/ASX 200 index (ASX: XJO) has fallen 0.12% today, Imugene shares are 5% in the green. They have now climbed 6% in two days.

Let's investigate further.

What's happening with Imugene this week?

The Imugene share price has benefitted from several tailwinds over the last few days.

Firstly, the company's ticker was added to the S&P/ASX 300 index by Standard and Poor's Dow Jones Indices (S&P DJI) on 3 September.

Imugene's inclusion came on the back of index rebalancing that takes place each quarter.

The decision to place a ticker into the index is based on several criteria, such as market capitalisation and liquidity. Obviously, Imugene shares fit the bill in that regard.

In addition, Imugene recently advised it had achieved positive results in its Phase 2 HER-Vaxx clinical trial.

The trial investigated the safety and efficacy profile of the company's immunotherapy candidate HER-Vaxx in a particular type of gastric cancer.

As a result of the positive data, Imugene now "plans two further company sponsored Phase 2 studies and one investigator sponsored study" investigating HER-vaxx's use as an intervention in HER-2 gastric cancer.

Finally, in further news that could be affecting the Imugene share price, the company announced today it had passed all resolutions at its "extraordinary general meeting of shareholders".

The resolutions were originally set out on 6 August. They pertained to shares that were supposed to be issued to Imugene's executive chair, Paul Hopper.

Hopper was due to receive these shares if the company reached a clinical milestone that resulted from Imugene's acquisition of Vaxina Pty Ltd, of which Hopper was the majority shareholder.

Specifically, the milestone was the US Food and Drug Administration (FDA) granting Imugene rights to a phase 1 clinical trial using Vaxina's CF33 oncology technology.

Due to a discrepancy in time zones and other unforeseeable factors, these shares were not transferred to Hopper. As such, the decision was left to shareholders to vote on the same.

Shareholders subsequently voted in favour of the exchange.

Imugene share price snapshot

The Imugene share price has climbed 315% this year to date, and 730% over the past 12 months.

Both of these results have far outpaced the broad index's return of around 25% over the past year.

Should you invest $1,000 in Allkem right now?

Before you buy Allkem shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Allkem wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough trading day for ASX stocks this Monday.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why 4DMedical, Gold Road, Syrah, and Tyro shares are racing higher today

These shares are starting the week strongly. But why?

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

2 ASX gold stocks racing higher in Monday's sinking market

Investors are sending these ASX gold stocks flying higher on Monday. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy finish to the week for ASX shares this Friday.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

5 ASX All Ords stocks rocketing higher this week

Investors sent these five ASX All Ords stocks soaring this week. But why?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today

These shares are having a good finish to the week. Let's find out why.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was the ASX's fourth day of gains for the week today.

Read more »